Karyopharm Therapeutics I... (KPTI)
Karyopharm Therapeutics Statistics
Share Statistics
Karyopharm Therapeutics has 8.57M shares outstanding. The number of shares has increased by 0.8% in one year.
| Shares Outstanding | 8.57M |
| Shares Change (YoY) | 0.8% |
| Shares Change (QoQ) | -0.46% |
| Owned by Institutions (%) | 48.72% |
| Shares Floating | 7.9M |
| Failed to Deliver (FTD) Shares | 31.36K |
| FTD / Avg. Volume | 24.27% |
Short Selling Information
The latest short interest is 1.83M, so 21.4% of the outstanding shares have been sold short.
| Short Interest | 1.83M |
| Short % of Shares Out | 21.4% |
| Short % of Float | 21.57% |
| Short Ratio (days to cover) | 12.69 |
Valuation Ratios
The PE ratio is -16.17 and the forward PE ratio is -0.64. Karyopharm Therapeutics's PEG ratio is 0.33.
| PE Ratio | -16.17 |
| Forward PE | -0.64 |
| PS Ratio | 8.51 |
| Forward PS | 0.1 |
| PB Ratio | -6.64 |
| P/FCF Ratio | -9.68 |
| PEG Ratio | 0.33 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Karyopharm Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.7, with a Debt / Equity ratio of -0.54.
| Current Ratio | 1.7 |
| Quick Ratio | 1.64 |
| Debt / Equity | -0.54 |
| Debt / EBITDA | -2.59 |
| Debt / FCF | -0.78 |
| Interest Coverage | -3.19 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $520.56K |
| Profits Per Employee | $-273.91K |
| Employee Count | 279 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.27 |
Taxes
| Income Tax | 57K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by -58.64% in the last 52 weeks. The beta is 0.59, so Karyopharm Therapeutics's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | -58.64% |
| 50-Day Moving Average | 6.09 |
| 200-Day Moving Average | 10.38 |
| Relative Strength Index (RSI) | 60.58 |
| Average Volume (20 Days) | 129.22K |
Income Statement
In the last 12 months, Karyopharm Therapeutics had revenue of 145.24M and earned -76.42M in profits. Earnings per share was -0.63.
| Revenue | 145.24M |
| Gross Profit | 139.23M |
| Operating Income | -119.44M |
| Net Income | -76.42M |
| EBITDA | -38.6M |
| EBIT | -38.94M |
| Earnings Per Share (EPS) | -0.63 |
Balance Sheet
The company has 62.48M in cash and 99.92M in debt, giving a net cash position of -37.45M.
| Cash & Cash Equivalents | 62.48M |
| Total Debt | 99.92M |
| Net Cash | -37.45M |
| Retained Earnings | -1.56B |
| Total Assets | 164.42M |
| Working Capital | 64.23M |
Cash Flow
In the last 12 months, operating cash flow was -127.49M and capital expenditures -142K, giving a free cash flow of -127.63M.
| Operating Cash Flow | -127.49M |
| Capital Expenditures | -142K |
| Free Cash Flow | -127.63M |
| FCF Per Share | -1.05 |
Margins
Gross margin is 95.86%, with operating and profit margins of -82.24% and -52.62%.
| Gross Margin | 95.86% |
| Operating Margin | -82.24% |
| Pretax Margin | -52.58% |
| Profit Margin | -52.62% |
| EBITDA Margin | -26.58% |
| EBIT Margin | -82.24% |
| FCF Margin | -87.88% |
Dividends & Yields
KPTI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KPTI is $54, which is 745.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $54 |
| Price Target Difference | 745.1% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Feb 26, 2025. It was a backward split with a ratio of 1:15.
| Last Split Date | Feb 26, 2025 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -12.65 |
| Piotroski F-Score | 3 |